-- Joincare Pharmaceutical (SHA:600380) received approval from China's National Medical Products Administration for the clinical trials of JKN2501 for injection, according to a Shanghai bourse disclosure on Thursday.
The drug, which inhibits bacterial β-lactamases, can be applied as a treatment for severe pneumonia, complicated urinary tract infections and other high-incidence infections.
The drug, in combination with meropenem, is currently undergoing phase I clinical trials as a treatment for urinary tract infections.
The pharmaceutical company invested 14.7 million yuan for the research and development of the drug.